ENTERO THERAPEUTICS INC (ENTO) Fundamental Analysis & Valuation

NASDAQ:ENTO • US33749P5070

Current stock price

2.99 USD
+0.15 (+5.28%)
At close:
3.2 USD
+0.21 (+7.02%)
After Hours:

This ENTO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ENTO Profitability Analysis

1.1 Basic Checks

  • In the past year ENTO has reported negative net income.
  • In the past year ENTO has reported a negative cash flow from operations.
  • In the past 5 years ENTO always reported negative net income.
  • ENTO had a negative operating cash flow in each of the past 5 years.
ENTO Yearly Net Income VS EBIT VS OCF VS FCFENTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • ENTO has a Return On Assets of -20.48%. This is in the better half of the industry: ENTO outperforms 75.33% of its industry peers.
  • The Return On Equity of ENTO (-31.45%) is better than 75.33% of its industry peers.
Industry RankSector Rank
ROA -20.48%
ROE -31.45%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENTO Yearly ROA, ROE, ROICENTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ENTO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENTO Yearly Profit, Operating, Gross MarginsENTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ENTO Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ENTO has been increased compared to 1 year ago.
  • There is no outstanding debt for ENTO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ENTO Yearly Shares OutstandingENTO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 500K 1M 1.5M
ENTO Yearly Total Debt VS Total AssetsENTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • ENTO has an Altman-Z score of -2.59. This is a bad value and indicates that ENTO is not financially healthy and even has some risk of bankruptcy.
  • ENTO has a Altman-Z score of -2.59. This is comparable to the rest of the industry: ENTO outperforms 46.54% of its industry peers.
  • ENTO has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • ENTO has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: ENTO outperforms 43.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -2.59
ROIC/WACCN/A
WACCN/A
ENTO Yearly LT Debt VS Equity VS FCFENTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • ENTO has a Current Ratio of 2.81. This indicates that ENTO is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.81, ENTO is not doing good in the industry: 67.66% of the companies in the same industry are doing better.
  • ENTO has a Quick Ratio of 2.81. This indicates that ENTO is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.81, ENTO is doing worse than 65.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.81
Quick Ratio 2.81
ENTO Yearly Current Assets VS Current LiabilitesENTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ENTO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 76.71% over the past year.
EPS 1Y (TTM)76.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ENTO will show a very strong growth in Earnings Per Share. The EPS will grow by 31.66% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-34.51%
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%
EPS Next 5Y31.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENTO Yearly Revenue VS EstimatesENTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 100M 200M 300M
ENTO Yearly EPS VS EstimatesENTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -100K -200K -300K

More info and screens

Find the best growth stocksShow best growing peers

0

4. ENTO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ENTO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENTO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENTO Price Earnings VS Forward Price EarningsENTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENTO Per share dataENTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

  • ENTO's earnings are expected to decrease with -13.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ENTO Dividend Analysis

5.1 Amount

  • ENTO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ENTO Fundamentals: All Metrics, Ratios and Statistics

ENTERO THERAPEUTICS INC

NASDAQ:ENTO (11/28/2025, 8:25:57 PM)

After market: 3.2 +0.21 (+7.02%)

2.99

+0.15 (+5.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11
Earnings (Next)03-30
Inst Owners4.54%
Inst Owner Change15.04%
Ins Owners2.89%
Ins Owner Change0%
Market Cap10.05M
Revenue(TTM)N/A
Net Income(TTM)-17.42M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.18
P/tB 0.19
EV/EBITDA N/A
EPS(TTM)-11.09
EYN/A
EPS(NY)-1.77
Fwd EYN/A
FCF(TTM)-0.86
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS0
BVpS16.48
TBVpS15.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.48%
ROE -31.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.81
Quick Ratio 2.81
Altman-Z -2.59
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.12%
EPS Next Y-34.51%
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%
EPS Next 5Y31.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y77.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.53%
OCF growth 3YN/A
OCF growth 5YN/A

ENTERO THERAPEUTICS INC / ENTO Fundamental Analysis FAQ

What is the fundamental rating for ENTO stock?

ChartMill assigns a fundamental rating of 1 / 10 to ENTO.


What is the valuation status of ENTERO THERAPEUTICS INC (ENTO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ENTERO THERAPEUTICS INC (ENTO). This can be considered as Overvalued.


How profitable is ENTERO THERAPEUTICS INC (ENTO) stock?

ENTERO THERAPEUTICS INC (ENTO) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for ENTO stock?

The Earnings per Share (EPS) of ENTERO THERAPEUTICS INC (ENTO) is expected to decline by -34.51% in the next year.